Intellia Therapeutics (NTLA) Projected to Post Earnings on Thursday

Key Points

• Intellia is slated to report Q1 2026 results pre-market on Thursday, May 14, with analysts forecasting EPS of ($0.92) and revenue of $13.806 million and a call at 8:00 AM ET.
• In its last quarter (reported Feb. 26) Intellia beat estimates, posting EPS of ($0.83) versus a ($0.99) consensus and revenue of $23.02 million, a 78.4% year-over-year increase.
• The stock trades around $13.85 with a market cap of $1.67 billion, a consensus analyst rating of "Hold" and an average price target of $20.09, while institutional investors own roughly 88.8% of shares.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) is projected to release its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.92) per share and revenue of $13.8060 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:00 AM ET.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The company had revenue of $23.02 million during the quarter, compared to analysts' expectations of $12.17 million. During the same quarter in the prior year, the business posted ($1.27) earnings per share. The company's revenue for the quarter was up 78.4% compared to the same quarter last year. On average, analysts expect Intellia Therapeutics to post $-4 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $13.85 on Thursday. Intellia Therapeutics has a 1 year low of $6.83 and a 1 year high of $28.25. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -3.62 and a beta of 1.93. The business has a fifty day moving average of $13.65 and a 200-day moving average of $12.49.

Analyst Ratings Changes

NTLA has been the subject of several recent analyst reports. Bank of America reissued a "neutral" rating on shares of Intellia Therapeutics in a research note on Monday, March 2nd. Canaccord Genuity Group increased their price target on Intellia Therapeutics from $48.00 to $58.00 and gave the stock a "buy" rating in a research note on Tuesday, April 28th. Citizens Jmp increased their price target on Intellia Therapeutics from $28.00 to $30.00 and gave the stock a "market outperform" rating in a research note on Tuesday, April 28th. JonesTrading raised Intellia Therapeutics from a "hold" rating to a "buy" rating and set a $29.00 price target for the company in a research note on Wednesday, March 4th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Intellia Therapeutics in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $20.09.

Institutional Trading of Intellia Therapeutics

Several institutional investors have recently modified their holdings of NTLA. AQR Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 154.1% in the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company's stock valued at $646,000 after buying an additional 55,118 shares during the period. Woodline Partners LP acquired a new stake in shares of Intellia Therapeutics in the first quarter valued at $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Intellia Therapeutics by 8.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company's stock valued at $3,709,000 after buying an additional 38,521 shares during the period. Creative Planning lifted its holdings in shares of Intellia Therapeutics by 12.9% in the second quarter. Creative Planning now owns 33,102 shares of the company's stock valued at $310,000 after buying an additional 3,795 shares during the period. Finally, Cetera Investment Advisers lifted its holdings in shares of Intellia Therapeutics by 47.4% in the second quarter. Cetera Investment Advisers now owns 33,532 shares of the company's stock valued at $315,000 after buying an additional 10,785 shares during the period. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.